Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 3/2016

01-03-2016 | Original Article

Metabolic syndrome in Sjögren’s syndrome patients: a relevant concern for clinical monitoring

Authors: Kristopherson Lustosa Augusto, Eloisa Bonfa, Rosa Maria Rodrigues Pereira, Cleonice Bueno, Elaine Pires Leon, Vilma Santos Trindade Viana, Sandra Gofinet Pasoto

Published in: Clinical Rheumatology | Issue 3/2016

Login to get access

Abstract

Metabolic syndrome (MetS) has been described in autoimmune diseases. However, there are scarce data about MetS and adipocytokine profile in primary Sjögren’s syndrome (pSS). Seventy-one female pSS patients (American-European Consensus Group Criteria, 2002) aged 18–65 years and 71 age-, race-matched control women were enrolled in this case–control study. Clinical data were collected by a standardized protocol. Blood levels of glucose, cholesterol, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), triglycerides, interleukin-1beta (IL-1beta)/IL-6, B-cell activating factor (BAFF), insulin, and leptin/adiponectin/visfatin/resistin were determined. Patients and controls were comparable regarding body mass index (BMI), smoking, sedentariness, and menopause (p > 0.05). MetS (39.4 vs. 16.9 %, p = 0.005), hypertension (p = 0.004), and dyslipidemia (p = 0.002) were more frequent in patients than controls. IL-1beta, IL-6, BAFF, resistin, and adiponectin levels were higher in patients than controls (p < 0.05). pSS patients with MetS (n = 28) had higher BMI, waist circumference, cholesterol, LDL-C, triglycerides, insulin, leptin and HOMA-IR values, and greater hypertension and diabetes rates than pSS patients without MetS (n = 43) (p < 0.05). Current and/or previous prednisone use (75.0 vs. 62.8 %, p = 0.313), current (3.0 ± 4.5 vs. 1.6 ± 3.2 mg/day, p = 0.299), and cumulative prednisone doses (p = 0.495) were similar in both groups. Otherwise, IL-1beta level was higher in MetS patients than in non-MetS patients (p = 0.012), and this finding was confirmed (p = 0.048) by multivariate analysis with adjustments for age, ethnicity, prednisone use, current and cumulative prednisone doses, and duration of use. We identified high MetS frequency and abnormal adipocytokine profile in pSS. The association of MetS with elevated IL-1beta level suggests that inflammation plays an important role in its pathogenesis.
Literature
1.
2.
Ramos-Casals M, Brito-Zerón P, Kostov B, Sisó-Almirall A, Bosch X, Buss D et al (2015) Google-driven search for big data in autoimmune geoepidemiology: analysis of 394,827 patients with systemic autoimmune diseases. Autoimmun Rev 14(8):670–679CrossRefPubMed
3.
4.
Chiorini JA, Cihakova D, Ouellette CE, Caturegli P (2009) Sjögren syndrome: advances in the pathogenesis from animal models. J Autoimmun 33(3–4):190–196CrossRefPubMedPubMedCentral
5.
Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X (2008) B-cell activating factor of the tumor necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren’s syndrome. Scand J Immunol 67(2):185–192CrossRefPubMed
6.
Dessein PH, Joffe BI, Veller MG, Stevens BA, Tobias M, Reddi K et al (2005) Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 32(3):435–442PubMed
7.
Sinicato NA, da Silva Cardoso PA, Appenzeller S (2013) Risk factors in cardiovascular disease in systemic lupus erythematosus. Curr Cardiol Rev 9(1):15–19PubMedPubMedCentral
8.
Pereira RM, de Carvalho JF, Bonfá E (2009) Metabolic syndrome in rheumatological diseases. Autoimmun Rev 8(5):415–419CrossRefPubMed
9.
10.
De Sanctis JB, Zabaleta M, Bianco NE, Garmendia JV, Rivas L (2009) Serum adipokine levels in patients with systemic lupus erythematosus. Autoimmunity 42(4):272–274CrossRefPubMed
11.
Guzik TJ, Mangalat D, Korbut R (2006) Adipocytokines—novel link between inflammation and vascular function? J Physiol Pharmacol 57(4):505–528PubMed
12.
Ramos-Casals M, Brito-Zerón P, Sisó A, Vargas A, Ros E, Bove A et al (2007) High prevalence of serum metabolic alterations in primary Sjögren’s syndrome: influence on clinical and immunological expression. J Rheumatol 34(4):754–761PubMed
13.
Pérez-De-Lis M, Akasbi M, Sisó A, Diez-Cascon P, Brito-Zerón P, Diaz-Lagares C et al (2010) Cardiovascular risk factors in primary Sjögren’s syndrome: a case–control study in 624 patients. Lupus 19(8):941–948CrossRefPubMed
14.
Juarez M, Toms TE, de Pablo P, Mitchell S, Bowman S, Nightingale P et al (2014) UK Primary Sjögren’s Syndrome Registry. Cardiovascular risk factors in women with primary Sjögren’s syndrome: United Kingdom primary Sjögren’s syndrome registry results. Arthritis Care Res (Hoboken) 66(5):757–764CrossRef
15.
Bartoloni E, Baldini C, Schillaci G, Quartuccio L, Priori R, Carubbi F et al. (2015) Cardiovascular disease risk burden in primary Sjögren’s syndrome: results of a population-based multicentre cohort study. J Intern Med 278(2):185--192
16.
Toussirot E, Gaugler B, Bouhaddi M, Nguyen NU, Saas P, Dumoulin G (2010) Elevated adiponectin serum levels in women with systemic autoimmune diseases. Mediat Inflamm 2010, 938408CrossRef
17.
Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554–558CrossRefPubMedPubMedCentral
18.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–1645CrossRefPubMed
19.
20.
Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E et al (2010) EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis 69(6):1103–1109CrossRefPubMedPubMedCentral
21.
Vandermeersch A, Ameye S, Puype D, Petitjean D, De Buyzere M, Langlois MR (2010) Estimation of the low-density lipoprotein (LDL) subclass phenotype using a direct, automated assay of small dense LDL-cholesterol without sample pretreatment. Clin Chim Acta 411(17–18):1361–1366CrossRefPubMed
22.
Szodoray P, Alex P, Brun JG, Centola M, Jonsson R (2004) Circulating cytokines in primary Sjögren’s syndrome determined by a multiplex cytokine array system. Scand J Immunol 59(6):592–599CrossRefPubMed
23.
Liu MY, Xydakis AM, Hoogeveen RC, Jones PH, Smith EO, Nelson KW et al (2005) Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system. Clin Chem 51(7):1102–1109CrossRefPubMed
24.
Ozgen M, Koca SS, Aksoy K, Dagli N, Ustundag B, Isik A (2011) Visfatin levels and intima-media thicknesses in rheumatic diseases. Clin Rheumatol 30(6):757–763CrossRefPubMed
25.
Borai A, Livingstone C, Kaddam I, Ferns G (2011) Selection of the appropriate method for the assessment of insulin resistance. BMC Med Res Methodol 11:158CrossRefPubMedPubMedCentral
26.
Ford ES, Giles WH, Mokdad AH (2004) Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 27(10):2444–2449CrossRefPubMed
27.
Cameron AJ, Shaw JE, Zimmet PZ (2006) The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 33(2):351–375CrossRef
28.
Polotsky HN, Polotsky AJ (2010) Metabolic implications of menopause. Semin Reprod Med 28(5):426–434CrossRefPubMed
29.
Sabio JM, Sánchez-Berná I, Martinez-Bordonado J, Vargas-Hitos JA, Navarrete-Navarrete N, Expósito Ruíz M et al (2015) Prevalence of and factors associated with increased arterial stiffness in patients with primary Sjögren’s syndrome. Arthritis Care Res (Hoboken) 67(4):554–562CrossRef
30.
Zardi EM, Sambataro G, Basta F, Margiotta DP, Afeltra AM (2014) Subclinical carotid atherosclerosis in elderly patients with primary Sjögren syndrome: a duplex Doppler sonographic study. Int J Immunopathol Pharmacol 27(4):645–651PubMed
31.
Gravani F, Papadaki I, Antypa E, Nezos A, Masselou K, Ioakeimidis D et al (2015) Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren’s syndrome: prevalence, clinical and laboratory associations. Arthritis Res Ther 17(1):99CrossRefPubMedPubMedCentral
32.
Chiang CH, Liu CJ, Chen PJ, Huang CC, Hsu CY, Chan WL et al (2014) Primary Sjögren’s syndrome and risk of ischemic stroke: a nationwide study. Clin Rheumatol 33(7):931–937CrossRefPubMed
33.
Parker B, Ahmad Y, Shelmerdine J, Edlin H, Yates AP, Teh LS et al (2011) An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. Lupus 20(14):1459–1465CrossRefPubMed
34.
Negrón AM, Molina MJ, Mayor AM, Rodríguez VE, Vilá LM (2008) Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. Lupus 17(4):348–354CrossRefPubMedPubMedCentral
35.
Chen X, Devaraj S (2014) Monocytes from metabolic syndrome subjects exhibit a proinflammatory M1 phenotype. Metab Syndr Relat Disord 12(7):362–366CrossRefPubMed
36.
Cojocaru M, Cojocaru IM, Silosi I, Rogoz S (2013) Role of leptin in autoimmune diseases. Maedica (Buchar) 8(1):61–74
37.
Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR et al (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334(5):292–295CrossRefPubMed
38.
Guo H, Callaway JB, Ting JP (2015) Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med 21(7):677–687CrossRefPubMed
39.
Baldini C, Rossi C, Ferro F, Santini E, Seccia V, Donati V et al (2013) The P2X7 receptor-inflammasome complex has a role in modulating the inflammatory response in primary Sjögren’s syndrome. J Intern Med 274(5):480–489CrossRefPubMed
40.
Norheim KB, Harboe E, Gøransson LG, Omdal R (2012) Interleukin-1 inhibition and fatigue in primary Sjögren’s syndrome—a double blind, randomised clinical trial. PLoS One 7(1), e30123CrossRefPubMedPubMedCentral
41.
García-Cáceres C, Fuente-Martín E, Díaz F, Granado M, Argente-Arizón P, Frago LM et al (2014) The opposing effects of ghrelin on hypothalamic and systemic inflammatory processes are modulated by its acylation status and food intake in male rats. Endocrinology 155(8):2868–2880CrossRefPubMed
42.
Bichile T, Petri M (2014) Prevention and management of co-morbidities in SLE. Presse Med 43(6 Pt 2):e187–e195CrossRefPubMed
43.
44.
Boström EA, d’Elia HF, Dahlgren U, Simark-Mattsson C, Hasséus B, Carlsten H et al (2008) Salivary resistin reflects local inflammation in Sjögren’s syndrome. J Rheumatol 35(10):2005–2011PubMed
45.
Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111(7):932–939CrossRefPubMed
Metadata
Title
Metabolic syndrome in Sjögren’s syndrome patients: a relevant concern for clinical monitoring
Authors
Kristopherson Lustosa Augusto
Eloisa Bonfa
Rosa Maria Rodrigues Pereira
Cleonice Bueno
Elaine Pires Leon
Vilma Santos Trindade Viana
Sandra Gofinet Pasoto
Publication date
01-03-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 3/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-015-3072-1

Other articles of this Issue 3/2016

Clinical Rheumatology 3/2016 Go to the issue

Original Article

Polyarthritis in primary Sjögren’s syndrome represents a distinct subset with less pronounced B cell proliferation a Dutch cohort with long-term follow-up

Original Article

Ultrasound7 versus ultrasound12 in monitoring the response to infliximab in patients with rheumatoid arthritis

Case Based Review

Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases

Case Based Review

Severe hyperferritinemia—a clue for severe hepatitis in a patient with adult-onset Still’s disease

Case Based Review

Mesenteric vasculitis in children with systemic lupus erythematosus

Brief Report

The prevalence of chondrocalcinosis of the symphysis pubis on CT scan and correlation with calcium pyrophosphate dihydrate crystal deposition disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits